Previous 10 | Next 10 |
2023-07-26 03:15:00 ET Summary Miller Value Partners is a value investor. It values businesses, and not just stocks, and invests in them for the long term. Miller Income Strategy's representative account generated a 3.14% net return in Q2 2023, outperforming the ICE BofA US High Y...
2023-07-21 08:30:00 ET In retirement, seniors on average see an annual shortfall of about $4,000 between the income they generate and the expenses they incur, according to data from the Bureau of Labor Statistics.. Whether you want to protect yourself from unexpected healthcare expense...
2023-07-17 08:05:00 ET Summary Organon, a global healthcare company, is a buy for value and income investors due to its strong growth in biosimilars business and 5.5% dividend yield. Despite a 20% YoY decline in adjusted EBITDA, the company has seen constant currency product sales...
VANCOUVER, BC / ACCESSWIRE / July 17, 2023 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to provide an update and forecast on its partner-funded project generation portfolio for 2023. Highlights Estimated 28,000 metres of partner funded drilling fo...
Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organ...
2023-07-16 01:17:15 ET Summary Organon & Co's share price has fallen significantly, with a p/e below the sector average and a 5.4% dividend yield, but its cash flows are barely above its nearly $300 million dividend, potentially limiting dividend growth. The company recently m...
2023-07-05 12:57:34 ET South Korea's Celltrion ( OTC:CONIF ) has launched a high-concentration, citrate-free formulated biosimilar of AbbVie's ( NYSE: ABBV ) Humira in the US. The biosimilar, which is called Yuflyma, was approved by the FDA in May. Yuflyma's list price is $6...
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN),...
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve access and affordability for patients and the US health care system ...
2023-07-01 16:00:00 ET Buoyed by booming sales of its diabetes drugs, Eli Lilly ( NYSE: LLY ) was the best performing large pharma or biotech in H1 2023, returning an impressive 28% . Coming in second, Vertex Pharmaceuticals ( VRTX ), helped by continued strong revenue f...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...